%0 Journal Article
%T Adapting Clinical Practice Guidelines for Chronic Kidney Disease: Blood Pressure Management and Kidney Replacement Therapy in Adults and Children in the Saudi Arabian Context Using the Grading of Recommendations Assessment, Development, and Evaluation-ADOLOPMENT Methodology.
%A Alhasan KA
%A Yepes-Nuñez JJ
%A Askandarani S
%A Amer YS
%A Al-Jelaify M
%A Almatham KI
%A Al-Ghonaim M
%A Al Dalbhi S
%A Kari JA
%A Mitwalli A
%A Memish ZA
%A Valson JS
%A Alvira X
%A Bilimoria K
%A Chawla R
%A Feit S
%A Bickett S
%A Brunnhuber K
%J Saudi J Kidney Dis Transpl
%V 34
%N 0
%D 2023 Dec 1
%M 38995286
暂无%R 10.4103/sjkdt.sjkdt_68_24
%X This practice guideline was developed by the chronic kidney disease (CKD) Task Force, which was composed of clinical and methodological experts. The Saudi Arabian Ministry of Health and its health holding company commissioned this guideline project to support the realization of Vision 2030's health-care transformation pillar. The synthesis of these guidelines was guided by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)- ADOLOPMENT methodology. The final guidelines addressed 12 clinical questions on the management of blood pressure in patients with CKD through a set of recommen-dations and performance measures. The recom-mendations included antihypertensive agents in children; renin- angiotensin system inhibition (RASi) versus non-RASi in adults; intensive versus standard blood pressure targets; early versus late assessment for kidney replacement therapy (KRT); late versus early preparation strategies for KRT; CKD symptoms during assessment for KRT or conservative manage-ment; initiation of KRT in patients with deteriorating CKD; choice of KRT modality or conservative management in certain CKD patient groups; changing or discontinuing KRT modalities; the frequency of reviews for KRT or conservative management; and information, education, and support. These conditional recommendations were based on a low to very low certainty of evidence, which highlights the need for high-quality randomized trials com-paring different antihypertensive agents in patients with CKD.